FDA Voted In Favor Of Pfizer’s RSV Vaccine Despite Safety Risks

The Pfizers vaccine was 66.7% effective at preventing RSV. Although a majority of the committee voted in favor, some members are concerned about the potential risks that come with the shot including Guillain-Barre syndrome.

The U.S. Food and Drug Administration voted in favor of a new vaccine.

Pfizer’s RSV vaccine for adults over the age of 60 was passed with a narrow vote of 7-4 with one abstention that there is “adequate data to support the safety and effectiveness of the vaccine for prevention of the respiratory disease.”

The Pfizers vaccine was 66.7% effective at preventing RSV. Although a majority of the committee voted in favor, some members are concerned about the potential risks that come with the shot including Guillain-Barre syndrome.

The FDA is scheduled to decide official approval of the vaccine by May. If approved, this will be the first ever vaccine made to prevent RSV disease.